Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum.
Ridker
Paul M
PM
D000209:Acute-Phase Proteins / Q000032:analysis; D015415:Biomarkers / Q000097:blood*; D002097:C-Reactive Protein / Q000032:analysis; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000175:diagnosis; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000097:blood / Q000150:complications* / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D009749:Nutrition Surveys; D011237:Predictive Value of Tests; D012306:Risk; D018570:Risk Assessment; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control*
D000209:Acute-Phase Proteins; D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002097:C-Reactive Protein